Condition

Primary Open-Angle Glaucoma (POAG)

ClinicalTrials.gov condition label

Clinical trials10
Recruiting2
Common interventions23
Lead sponsors shown7

Clinical trials

10 shown
Aqueous Humor and Ocular Tissue Analysis in Glaucoma and CataractNCT07462000 · 2026-01-21
RECRUITING
GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle GlaucomaNCT06921317 · 2025-11-19
RECRUITING
Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECHNCT07690397 · 2026-06-10
ACTIVE_NOT_RECRUITING
Personalized Mobile Reminders for Medication Adherence and Intraocular Pressure Control in Primary Open-Angle GlaucomaNCT07480577 · 2026-04-01
NOT_YET_RECRUITING
Effect of Niacinamide Supplementation in GlaucomaNCT07007260 · 2024-02-20
COMPLETED
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)NCT06437639 · 2023-09-15
COMPLETED
Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)NCT06903156 · 2021-11-15
COMPLETED
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAGNCT02829996 · 2016-08-19
COMPLETED
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle GlaucomaNCT02565173 · 2015-09-01
COMPLETED
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle GlaucomaNCT01917383 · 2013-08-01
COMPLETED

Common interventions

MexidolDRUG2Digital Reminder InterventionBEHAVIORAL1GVB-2001-high doseDRUG1GVB-2001-low doseDRUG1LatanoprostDRUG1latanoprost 0.0025% QDDRUG1latanoprost 0.005% QDDRUG1niacinamide supplementationDIETARY_SUPPLEMENT1Phacoemulsification With Intraocular Lens ImplantationPROCEDURE1Phacoemulsification With Intraocular Lens Implantation and Deep SclerectomyPROCEDURE1PlaceboOTHER1placebo BIDDRUG1Preservative dorzolamide-timolol-brimonidine combinationCOMBINATION_PRODUCT1Preservative-free dorzolamide-timolol-brimonidine combinationCOMBINATION_PRODUCT1TimololDRUG1timolol 0.5% BIDDRUG1TrabodenosonDRUG1trabodenoson 3.0% / latanoprost 0.005% QDDRUG1trabodenoson 3.0% QDDRUG1trabodenoson 4.5% BIDDRUG1trabodenoson 6.0% / latanoprost 0.0025% QDDRUG1trabodenoson 6.0% / latanoprost 0.005% QDDRUG1trabodenoson 6.0% QDDRUG1

Trial status mix

COMPLETED6
RECRUITING2
ACTIVE_NOT_RECRUITING1
NOT_YET_RECRUITING1

Phase mix

PHASE24
NA3
PHASE42
PHASE11
PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.